Any feedback?
Literature summary for 3.5.2.6 extracted from
- Hyperproduction of inhibitor-susceptible TEM beta-lactamase is responsible for resistance of Serratia marcescens to beta-lactam-beta-lactamase inhibitor combinations (2008), Chemotherapy, 54, 31-37.
Cloned(Commentary)
| Cloned (Comment) | Organism |
|---|---|
| expressed in Escherichia coli strain HB101 | Serratia marcescens |
Inhibitors
| Inhibitors | Comment | Organism | Structure |
|---|---|---|---|
| clavulanate | 62.2-92.1% of activity is inhibited after preincubation with 0.1 mM clavulanate | Serratia marcescens |  |
| EDTA | 0.1 mM EDTA inhibits only 4.8-26.8% of the activity of the TEM-type beta-lactamase | Serratia marcescens | |
| additional information | shows high-level resistance to expanded-spectrum cephalosporins and beta-lactam clavulanate combinations | Serratia marcescens |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Serratia marcescens | - |
- |
- |
Substrates and Products (Substrate)
| Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
|---|---|---|---|---|---|---|
| nitrocefin + H2O | - |
Serratia marcescens | (2R)-2-{(R)-carboxy[2-(thiophen-2-yl)acetamido]methyl}-5-[(E)-2-(2,4-dinitrophenyl)ethenyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid | - |
? | |
Synonyms
| Synonyms | Comment | Organism |
|---|---|---|
| TEM-type beta-lactamase | - |
Serratia marcescens |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
